On Friday, Akebia Therapeutics Inc. (NASDAQ: AKBA) opened lower -4.58% from the last session, before settling in for the closing price of $1.53. Price fluctuations for AKBA have ranged from $0.59 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 5.16% over the past five years. Company’s average yearly earnings per share was noted 0.32% at the time writing. With a float of $186.68 million, this company’s outstanding shares have now reached $194.58 million.
Let’s look at the performance matrix of the company that is accounted for 167 employees.
Akebia Therapeutics Inc. (AKBA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Akebia Therapeutics Inc. is 10.84%, while institutional ownership is 18.43%. The most recent insider transaction that took place on Feb 29 ’24, was worth 73,581. In this transaction CEO and President of this company sold 46,570 shares at a rate of $1.58, taking the stock ownership to the 2,044,580 shares. Before that another transaction happened on Feb 29 ’24, when Company’s SVP, Chief Operating Officer sold 8,661 for $1.58, making the entire transaction worth $13,684. This insider now owns 706,932 shares in total.
Akebia Therapeutics Inc. (AKBA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 46.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.32% per share during the next fiscal year.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Trading Performance Indicators
Check out the current performance indicators for Akebia Therapeutics Inc. (AKBA). In the past quarter, the stock posted a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.27 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics Inc. (NASDAQ: AKBA) saw its 5-day average volume 4.01 million, a negative change from its year-to-date volume of 4.46 million. As of the previous 9 days, the stock’s Stochastic %D was 18.26%. Additionally, its Average True Range was 0.17.
During the past 100 days, Akebia Therapeutics Inc.’s (AKBA) raw stochastic average was set at 33.27%, which indicates a significant increase from 3.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 114.35% in the past 14 days, which was higher than the 84.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6246, while its 200-day Moving Average is $1.3040. Nevertheless, the first resistance level for the watch stands at $1.5267 in the near term. At $1.5933, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6467. If the price goes on to break the first support level at $1.4067, it is likely to go to the next support level at $1.3533. The third support level lies at $1.2867 if the price breaches the second support level.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Key Stats
There are currently 209,372K shares outstanding in the company with a market cap of 305.68 million. Presently, the company’s annual sales total 194,620 K according to its annual income of -51,930 K. Last quarter, the company’s sales amounted to 56,070 K and its income totaled -50 K.
